{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:13:34Z","timestamp":1788966814141,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Cancer Society, Advisory Board"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K08CA279644-01A1"],"award-info":[{"award-number":["1K08CA279644-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>AbstractAbstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognostic and predictive value of O6-methylguanine-DNA methyltransferase promoter (MGMTp) methylation is not well established in isocitrate dehydrogenase (IDH)-mutant gliomas. This study evaluates the survival impact of MGMTp and other clinical, molecular, and radiologic variables in low-grade and high-grade IDH-mutant gliomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated 520 consecutive adult patients treated for an initial diagnosis of IDH-mutant glioma, of any histological grade, at two large academic institutions. MGMTp methylation was evaluated by methylation-specific polymerase chain reaction (PCR) analysis. Log-rank test and Cox proportional hazards model were applied to evaluate the association of clinical, molecular, and radiological characteristics with overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age was 36.6 years; MGMTp was methylated in 70% and unmethylated in 30%. MGMTp methylation was not significantly associated with OS (P = 0.11) or PFS (P = 0.74) on multivariate analyses. Cyclin dependent kinase inhibitor 2A\/B (CDKN2A\/B) homozygous deletion [HR\u2009=\u20093.26 (1.47, 7.23), P\u2009=\u2009.006] and an integrated grade 4 classification [HR\u2009=\u20092.08 (1.06, 4.67), P\u2009=\u2009.048] were strong predictors of OS in astrocytoma, whereas maximal resection [HR\u2009=\u20090.06 (0.01, 0.57), p\u2009=\u20090.016] and radiation [HR\u2009=\u20090.41 (0.18, 0.91), P\u2009=\u2009.03] were strong prognosticators for PFS in the entire cohort. Maximal resection of the enhancing disease [HR\u2009=\u20090.17 (0.05, 0.96), P\u2009=\u2009.014] and radiation [HR\u2009=\u20090.47 (0.19, 0.65), P\u2009=\u2009.046] were strongly associated with PFS in grade 2 and 3 gliomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MGMTp methylation was not associated with a prognostic or predictive value in our IDH-mutant glioma cohort. CDKN2A\/B status and extent of resection were strong predictors of outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf287","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T12:57:33Z","timestamp":1765630653000},"page":"752-764","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-7692","authenticated-orcid":false,"given":"Gilbert","family":"Youssef","sequence":"first","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-5017","authenticated-orcid":false,"given":"Elisa","family":"Aquilanti","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie J","family":"Miller","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Lan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Center for Clinical Investigation, Brigham and Women\u2019s Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-5103","authenticated-orcid":false,"given":"Aleksandra B","family":"Lasica","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-1225","authenticated-orcid":false,"given":"Isabel","family":"Arrillaga-Romany","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy T","family":"Batchelor","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Department of Neurology, Brigham and Women\u2019s Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar R","family":"Berger","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameen","family":"Beroukhim","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-9535","authenticated-orcid":false,"given":"Ugonma","family":"Chukwueke","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-0136","authenticated-orcid":false,"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A","family":"Forst","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Gerstner","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Nicolas Gonzalez","family":"Castro","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Department of Neurology, Brigham and Women\u2019s Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T","family":"Jordan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Ricardo","family":"Mcfaline-Figueroa","sequence":"additional","affiliation":[{"name":"Brain & Spine Tumor Center, Perlmutter Cancer Center, NYU Langone Health , New York"},{"name":"Department of Neurology, Grossman School of Medicine, New York University , New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Quant","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2725-8717","authenticated-orcid":false,"given":"Lakshmi","family":"Nayak","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2941-9740","authenticated-orcid":false,"given":"Vihang","family":"Nakhate","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Ospina","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R","family":"Plotkin","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Wang","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Y","family":"Rhee","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"},{"name":"Division of Adult Palliative Care, Department of Supportive Oncology, Dana-Farber Cancer Institute , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Reardon","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-7700","authenticated-orcid":false,"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston"},{"name":"Harvard Medical School, Harvard University , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2026041216253891000_noaf287-B1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/jcp.25896","article-title":"The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials","volume":"233","author":"Binabaj","year":"2018","journal-title":"J Cell Physiol"},{"key":"2026041216253891000_noaf287-B2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"2026041216253891000_noaf287-B3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jocn.2020.12.028","article-title":"Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas","volume":"85","author":"Haque","year":"2021","journal-title":"J Clin Neurosci"},{"key":"2026041216253891000_noaf287-B4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00401-018-1810-6","article-title":"The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033","volume":"135","author":"Bady","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026041216253891000_noaf287-B5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.20892\/j.issn.2095-3941.2020.0179","article-title":"Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma","volume":"18","author":"Chai","year":"2021","journal-title":"Cancer Biol Med"},{"key":"2026041216253891000_noaf287-B6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/jamaoncol.2018.1977","article-title":"Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology\/RTOG 0424 trial","volume":"4","author":"Bell","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026041216253891000_noaf287-B7","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00701-016-2928-8","article-title":"The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy","volume":"158","author":"Millward","year":"2016","journal-title":"Acta Neurochir (Wien)"},{"key":"2026041216253891000_noaf287-B8","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/neuonc\/noab039","article-title":"MGMT promoter methylation is associated with patient age and 1p\/19q status in IDH-mutant gliomas","volume":"23","author":"Horbinski","year":"2021","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/neuonc\/now133","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1186\/s12885-019-6177-0","article-title":"Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation","volume":"19","author":"Brito","year":"2019","journal-title":"BMC Cancer"},{"key":"2026041216253891000_noaf287-B11","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.2217\/fon-2017-0634","article-title":"The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?","volume":"14","author":"Franceschi","year":"2018","journal-title":"Future Oncol"},{"key":"2026041216253891000_noaf287-B12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2026041216253891000_noaf287-B13","doi-asserted-by":"publisher","first-page":"vdac030","DOI":"10.1093\/noajnl\/vdac030","article-title":"Prognostic value of O 6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas","volume":"4","author":"Lam","year":"2022","journal-title":"Neurooncol Adv"},{"key":"2026041216253891000_noaf287-B14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11060-023-04515-z","article-title":"MGMT promoter methylation in 1p19q-intact gliomas","volume":"166","author":"Kinslow","year":"2024","journal-title":"J Neurooncol"},{"key":"2026041216253891000_noaf287-B15","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1093\/neuonc\/noae157","article-title":"MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma","volume":"26","author":"Lim-Fat","year":"2024","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00401-023-02662-1","article-title":"Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma","volume":"147","author":"Weller","year":"2024","journal-title":"Acta Neuropathol"},{"key":"2026041216253891000_noaf287-B17","doi-asserted-by":"publisher","first-page":"noaf133","DOI":"10.1093\/neuonc\/noaf133","article-title":"Clinical, molecular and radiological predictors of prognosis in newly diagnosed astrocytoma. IDH-mutant, WHO grade 4","volume":"29","author":"Lasica","year":"2025","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B18","first-page":"67","article-title":"Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients","volume":"59","author":"Esteller","year":"1999","journal-title":"Cancer Res"},{"key":"2026041216253891000_noaf287-B19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ng.3273","article-title":"Mutational landscape and clonal architecture in grade II and III gliomas","volume":"47","author":"Suzuki","year":"2015","journal-title":"Nat Genet"},{"key":"2026041216253891000_noaf287-B20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2026041216253891000_noaf287-B21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"2026041216253891000_noaf287-B22","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1001\/jama.2015.15281","article-title":"Multiple imputation: a flexible tool for handling missing data","volume":"314","author":"Li","year":"2015","journal-title":"JAMA"},{"key":"2026041216253891000_noaf287-B23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1001\/jamaoncol.2023.0990","article-title":"Association of MGMT promoter methylation with survival in low-grade and anaplastic gliomas after alkylating chemotherapy","volume":"9","author":"Kinslow","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026041216253891000_noaf287-B24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/1477-7819-11-284","article-title":"Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in japanese malignant glioma patients","volume":"11","author":"Takahashi","year":"2013","journal-title":"World J Surg Oncol"},{"key":"2026041216253891000_noaf287-B25","doi-asserted-by":"publisher","first-page":"19758","DOI":"10.1038\/s41598-020-76312-x","article-title":"Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II","volume":"10","author":"Karschnia","year":"2020","journal-title":"Sci Rep"},{"key":"2026041216253891000_noaf287-B26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","article-title":"cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas","volume":"139","author":"Brat","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2026041216253891000_noaf287-B27","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/neuonc\/noab088","article-title":"Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p\/19q deleted anaplastic glioma","volume":"23","author":"Tesileanu","year":"2021","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B28","doi-asserted-by":"publisher","first-page":"v25","DOI":"10.1093\/neuonc\/noaf201.0097","article-title":"Biom-09. PROGNOSTIC and predictive markers for outcome in patients with idhmt tumors treated in the eortc catnon trial on adjuvant and\/or concurrent temozolomide in anaplastic astrocytoma","volume":"27","author":"van den Bent","year":"2025","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B29","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1200\/JCO.2025.43.16_suppl.2065","article-title":"Association of MGMT status with survival in low and high-grade IDH-mutant astrocytomas","volume":"43","author":"Schwetye","year":"2025","journal-title":"JCO"},{"key":"2026041216253891000_noaf287-B30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010","journal-title":"Acta Neuropathol"},{"key":"2026041216253891000_noaf287-B31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"Mj van den","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026041216253891000_noaf287-B32","doi-asserted-by":"publisher","first-page":"103485","DOI":"10.1016\/j.esmoop.2024.103485","article-title":"Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study","volume":"9","author":"Dipasquale","year":"2024","journal-title":"ESMO Open"},{"key":"2026041216253891000_noaf287-B33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","article-title":"MGMT status as a clinical biomarker in glioblastoma","volume":"6","author":"Butler","year":"2020","journal-title":"Trends Cancer"},{"key":"2026041216253891000_noaf287-B34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1479-5876-10-250","article-title":"MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy","volume":"10","author":"Melguizo","year":"2012","journal-title":"J Transl Med"},{"key":"2026041216253891000_noaf287-B35","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/neuonc\/noad160","article-title":"Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group","volume":"26","author":"Karschnia","year":"2024","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B37","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/JCO.2025.43.16_suppl.2001","article-title":"A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: a report by the RANO resect group","volume":"43","author":"Karschnia","year":"2025","journal-title":"JCO"},{"key":"2026041216253891000_noaf287-B38","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1158\/1078-0432.CCR-24-0901","article-title":"Differences in the prognostic role of age, extent of resection, and tumor grade between astrocytoma IDHmt and oligodendroglioma: a Single-Center cohort study","volume":"30","author":"van der Vaart","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026041216253891000_noaf287-B39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/neuonc\/nox176","article-title":"The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis","volume":"20","author":"Wijnenga","year":"2018","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B40","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1200\/JCO.21.02929","article-title":"Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma","volume":"41","author":"Hervey-Jumper","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026041216253891000_noaf287-B41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/nan.12523","article-title":"Integrated molecular characterization of IDH-mutant glioblastomas","volume":"45","author":"Korshunov","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2026041216253891000_noaf287-B42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","article-title":"Novel, improved grading system(s) for IDH-mutant astrocytic gliomas","volume":"136","author":"Shirahata","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026041216253891000_noaf287-B43","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/neuonc\/noz124","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay","year":"2019","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B44","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1093\/neuonc\/noad095","article-title":"Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas","volume":"25","author":"Kocakavuk","year":"2023","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B45","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00401-023-02639-0","article-title":"CDKN2A\/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas","volume":"146","author":"Hickman","year":"2023","journal-title":"Acta Neuropathol"},{"key":"2026041216253891000_noaf287-B46","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/neuonc\/now085","article-title":"Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p\/19q co-deleted anaplastic oligodendrogliomas","volume":"18","author":"Figarella-Branger","year":"2016","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B47","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/neuonc\/noae107","article-title":"The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?","volume":"26","author":"van den Bent","year":"2024","journal-title":"Neuro-Oncol"},{"key":"2026041216253891000_noaf287-B48","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041216253891000_noaf287-B49","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"Van Den Bent","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf287\/65900991\/noaf287.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/3\/752\/65900991\/noaf287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/3\/752\/65900991\/noaf287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T20:25:46Z","timestamp":1776025546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/3\/752\/8380362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf287","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,15]]}}}